The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

A research team from POSTECH has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

A research team has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

A research team led by Professor Won Jong Kim from the Department of Chemistry at POSTECH, in collaboration with the Korea ...

Russell Broadbent and a group comprising scientists, health professionals, lawyers, and academics, wrote to the Prime ...

The global Oligonucleotide CDMO Market, valued at US$2.33 billion in 2023, is forecasted to grow at a robust CAGR of 21.8%, ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in ...

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

including LUNAR® lipid nanoparticle formulation processes and STARR® sa-mRNA drug substance manufacturing.” ...

The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...